VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31

Virax Biolabs Group Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026

$1.40−0.05 (-3.45%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Virax Biolabs Group Ltd balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-04-01
Cash & Equivalents	6.44	4.23	3.59	9.35	0.02	0.02	0.02
Cash & Short-Term Investments	6.44	4.23	3.59	9.35	0.02	0.02	0.02
Receivables	–	–	–	–	–	0.00	–
Inventory	0	0.09	0.06	0	0.02	0.02	–
Total Current Assets	6.83	4.89	4.38	9.63	0.05	0.04	–
Property, Plant & Equipment	1.17	1.23	0.90	–	–	–	–
Operating Lease Right-of-Use Assets	0.33	0.31	0.21	–	–	–	–
Intangible Assets	–	–	–	0.18	–	–	–
Deferred Tax Assets	2.50	1.33	1.43	0.98	0.57	0.44	–
Total Assets	8.32	6.43	5.48	9.81	0.05	0.04	–
Current Portion of Leases	0.08	0.05	0.05	–	–	–	–
Total Current Liabilities	0.69	0.67	0.17	0.91	1.25	0.87	–
Long-Term Leases	0.30	0.29	0.18	–	–	–	–
Operating Lease Liabilities	0.39	0.34	0.22	0	–	–	–
Total Liabilities	0.99	0.96	0.35	0.91	1.25	0.87	–
Common Stock	0.01	0.00	0.00	0.00	0.00	–	–
Retained Earnings	-30	-25	-19	-12	-6.34	-4.63	–
Shareholders' Equity	7.58	5.70	5.37	9.13	-0.97	-0.65	–
Noncontrolling Interest	-0.24	-0.23	-0.23	-0.22	-0.22	-0.18	–
Total Equity	7.33	5.46	5.14	8.90	-1.20	-0.83	-1.22
Total Liabilities & Equity	8.32	6.43	5.48	9.81	0.05	0.04	–
Shares Outstanding(shares)	0.58	0.17	0.10	0.06	0.04	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 61.9%
Operating margin: -51515.2%
Net margin: -40439.1%
Return on equity, FY2026: -75.7%

Financial strength

Current ratio: 9.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 940.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –